JAIPUR, India, March 2, 2026 /PRNewswire/ -- Genus Power (NSE: GENUSPOWER) (BSE: 530343), India's leading end-to-end energy measurement and advanced metering solutions provider, has crossed a sign...

JAIPUR, India, March 2, 2026 /PRNewswire/ -- Genus Power (NSE: GENUSPOWER) (BSE: 530343), India's leading end-to-end energy measurement and advanced metering solutions provider, has crossed a significant milestone of over 26 million smart meter deployment worldwide, reinforcing its...

Rajasthan-based smart metering solutions and service provider Genus Power has deployed 10 million smart meters under the Revamped Distribution Sector Scheme (RDSS) across nine states. Under RDSS, India aims to replace 250 million conventional meters with smart meters by 2028. In addition, another 15 million meters manufactured by Genus have been deployed through other advanced metering infrastructure service providers and utility partners, taking the total number of Genus smart meters operational in India to 25 million.

In this briefing: Business Brain Showa Ota (9658 JP): Q3 FY03/26 flash update HK A+H IPO 2025 Cornerstone Lock-Up Expiry: Price and Liquidity Evidences Aequitas: PhonePe Pre-IPO - The Negatives - Near Term Growth Might Be Capped Broadleaf (3673 JP): Full-year FY12/25 flash update Genus Power Infrastructures Ltd - Q3 Sees Seasonal Moderation; Tendering Progress Will Be the Key 1. Business Brain Showa Ota (9658 JP): Q3 FY03/26 flash update In Q3 FY03/26, revenue rose to JPY31.1bn (+10.0% YoY), driven by Consulting and System Development (+14.8% YoY). Business income increased to JPY2.5bn (+11.6% YoY) with operating profit at JPY2.4bn (+11.2% YoY). BPO & Managed Services revenue grew to JPY7.5bn (+10.8% YoY), despite declines in HR payroll BPO and managed services. 2. HK A+H IPO 2025 Cornerstone Lock-Up Expiry: Price and Liquidity Evidences We examine H-share trading behavior around the six-month cornerstone lock-up expiry for A+H listings since 2025, assessing whether these events create systematic price pressure or primarily affect liquidity.

In this briefing: HK A+H IPO 2025 Cornerstone Lock-Up Expiry: Price and Liquidity Evidences Aequitas: PhonePe Pre-IPO - The Negatives - Near Term Growth Might Be Capped Broadleaf (3673 JP): Full-year FY12/25 flash update Genus Power Infrastructures Ltd - Q3 Sees Seasonal Moderation; Tendering Progress Will Be the Key NetEase (NTES US) - 4Q25 Results: Strong Contract Liabilities Growth Despite Revenue Miss 1. HK A+H IPO 2025 Cornerstone Lock-Up Expiry: Price and Liquidity Evidences We examine H-share trading behavior around the six-month cornerstone lock-up expiry for A+H listings since 2025, assessing whether these events create systematic price pressure or primarily affect liquidity. We align each stock around its expiry date (T0) and analyze price and trading volume, incorporating both market-adjusted returns and a measure of overhang intensity relative to typical liquidity. Elevated trading activity emerges around expiry, but we find no consistent aggregate post-expiry underperformance; overhang intensity appears more linked to liquidity shifts than directional price moves. 2.

In this briefing: Aequitas: PhonePe Pre-IPO - The Negatives - Near Term Growth Might Be Capped Pharmaceuticals: IPM: steady 11% growth in Jan-26 Man Infraconstruction Ltd - Q3FY26: Slower Momentum; Recovery Awaited Arvind SmartSpaces Ltd - Q3FY26: Execution-Led Growth with Strengthening BD Momentum Genus Power Infrastructures Ltd - Q3 Sees Seasonal Moderation; Tendering Progress Will Be the Key 1. Aequitas: PhonePe Pre-IPO - The Negatives - Near Term Growth Might Be Capped Phonepe (PPL) is looking to raise up to US$1.35bn in its upcoming India IPO. PhonePe Ltd (PPL) is a fintech firm that builds digital platforms for payments services, digital distribution and financial services, offering consumer payments, merchant payments and lending and insurance distribution services. In this note, we talk about the not-so-positive aspects of the deal. 2. Pharmaceuticals: IPM: steady 11% growth in Jan-26 As per IQVIA, IPM recorded strong growth for Jan-26 at 11% YoY (vs 15% in Dec-25), units grew by 1.1% YoY (4.4%% in Dec-25).

In this briefing: Broadleaf (3673 JP): Full-year FY12/25 flash update Genus Power Infrastructures Ltd - Q3 Sees Seasonal Moderation; Tendering Progress Will Be the Key NetEase (NTES US) - 4Q25 Results: Strong Contract Liabilities Growth Despite Revenue Miss Melco Holdings (6676 JP): Q3 FY03/26 flash update Freee (4478) 1. Broadleaf (3673 JP): Full-year FY12/25 flash update FY12/25 revenue rose 15.4% YoY to JPY20.8bn, with operating profit increasing 206.0% YoY to JPY2.1bn. FY12/26 forecasts: revenue JPY23.5bn (+12.9% YoY), operating profit JPY4.8bn (+132.7% YoY), dividend payout ratio 42.4%. Cloud services revenue increased 44.1% YoY; package system revenue declined 23.5% YoY due to cloud transition. 2. Genus Power Infrastructures Ltd - Q3 Sees Seasonal Moderation; Tendering Progress Will Be the Key Addressable Market: Against the RDSS’s Smart Meter Installation target of 25 Cr, ~15 Cr meters have been awarded, and 5.6 Cr are installed (~2.5 Cr meters are supplied by Genus). Out of the remaining 10 Cr meters to be awarded, tenders for 5 Cr meters are live; however, execution timelines in some large states, particularly Tamil Nadu (~3 Cr meters), may face delays of 4-6 months due to the election-related process.

In this briefing: Pharmaceuticals: IPM: steady 11% growth in Jan-26 Man Infraconstruction Ltd - Q3FY26: Slower Momentum; Recovery Awaited Arvind SmartSpaces Ltd - Q3FY26: Execution-Led Growth with Strengthening BD Momentum Genus Power Infrastructures Ltd - Q3 Sees Seasonal Moderation; Tendering Progress Will Be the Key Britannia Industries Ltd. - Margin Stability Powering a Sharper Growth Revival; Maintain BUY 1. Pharmaceuticals: IPM: steady 11% growth in Jan-26 As per IQVIA, IPM recorded strong growth for Jan-26 at 11% YoY (vs 15% in Dec-25), units grew by 1.1% YoY (4.4%% in Dec-25). Growth was led by CVS, anti-diabetes, CNS, VMN, and oncology segments, while growth in anti-infective, gastro, respiratory, derma, and pain grew at par or marginal below compared to IPM growth. Our view: IPM growth was steady at 11% YoY in Jan-26, largely led by price growth and traction in chronic therapies. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.